Helix Competitors

Pink Sheets . USA . 
Stock . Helix BioPharma Corp
HBPCF Stock  USD 1.73  0.00  0.00%   
Helix BioPharma Corp competes with Relief Therapeutics, Calliditas Therapeutics, Relief Therapeutics, Arch Biopartners, and Zivo Bioscience; as well as few others. The company classifies itself under Biotechnology sector and is part of Health Care industry. Analyzing Helix BioPharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Helix BioPharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Helix BioPharma Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Helix BioPharma competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Helix BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.091.7325.27
Details
Intrinsic
Valuation
LowRealHigh
0.091.7625.30
Details
Naive
Forecast
LowNextHigh
0.031.5125.05
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.551.492.42
Details

Helix BioPharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Helix BioPharma and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Helix and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Helix BioPharma Corp does not affect the price movement of the other competitor.

High positive correlations

RLFTF
+ 0.85
RLFTY
ZIVO
+ 0.78
PSYBF
VICP
+ 0.58
INNMF
RLFTF
+ 0.56
PSYBF
VICP
+ 0.56
PSYBF
ZIVO
+ 0.51
RLFTF
  

High negative correlations

OTLC
- 0.52
ACHFF
ZIVO
- 0.46
ACHFF
ACHFF
- 0.46
PSYBF
VICP
- 0.35
OTLC
OTLC
- 0.29
INNMF
ACHFF
- 0.18
RLFTF

Risk-Adjusted Indicators

There is a big difference between Helix Pink Sheet performing well and Helix BioPharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Helix BioPharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
RLFTY  6.25  1.34  0.07  3.13  10.05 
(10.68)
 9.59 
(7.41)
 132.30 
CLTEF  60.83  30.23  0.79 (0.88) 19.48 
(212.93)
 28.95 
(27.16)
 1,027 
PSYBF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
RLFTF  6.02  0.58  0.03 (2.95) 10.91 
(6.95)
 10.91 
(9.19)
 78.78 
ACHFF  2.08  0.03  0.00  0.05  0.00 
 0.00 
 3.03 
(5.26)
 19.05 
INNMF  8.13  1.26  0.04 (0.22) 9.92 
(27.79)
 29.87 
(16.67)
 128.67 
ZIVO  6.59 (0.40) 0.00  9.52  0.00 
 0.00 
 16.92 
(20.26)
 55.70 
TCNAF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
OTLC  4.66  0.31  0.03  0.25  5.00 
(14.01)
 14.29 
(10.00)
 38.33 
VICP  0.46 (0.20) 0.00  0.49  0.00 
 0.00 
 0.00 
 0.00 
 15.25 
All Fundamental Data

Helix BioPharma Competitive Analysis

The better you understand Helix BioPharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Helix BioPharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Helix BioPharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HBPCF RLFTY CLTEF RLFTF ACHFF INNMF ZIVO TCNAF OTLC VICP
 0.00 
 1.73 
Helix
 12.57 
 3.85 
Relief
 27.27 
 0.70 
Calliditas
 3.28 
 2.95 
Relief
 1.10 
 0.90 
Arch
 0.00 
 0.10 
Amplia
 3.85 
 7.00 
Zivo
 0.00 
 0.0001 
TransCanna
 2.50 
 0.08 
Oncotelic
 0.00 
 1.50 
Vicapsys
Market Volatility
(90 Days Market Risk)
Out of control
Abnormally volatile
Out of control
Extremely Dangerous
Extremely Dangerous
Out of control
Risky
Very steady
Out of control
Unstable
Market Performance
(90 Days Performance)
Fair
Mild
Good
Weak
Weakest
Mild
Weakest
Weakest
Soft
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Fair
Fair
Moderate
Low
High
Risky
High
Moderate
Risky
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Hold
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
0.69
2.8
7.48
2.8
0.75
31.18
2.08
0.07
0.03
0.03
Net Asset
3.73 M
251.62 M
1.46 B
251.62 M
621.64 K
24.48 M
1.64 M
25.64 M
23.61 M
404.12 K
Profit Margin
N/A
N/A
-1.55
N/A
-1.46
-1.75
N/A
N/A
N/A
N/A
EBITDA
(6.53 M)
(33.3 M)
(524.46 M)
(33.3 M)
(1.08 M)
(3.64 M)
(13.36 M)
(10.03 M)
(8.45 M)
(734.42 K)
Current Valuation
30.65 M
102.36 M
496.05 M
102.36 M
136.63 M
4.82 M
27.98 M
16.58 M
31.34 M
31.17 M
Price To Book
134.72
0.77
5.22
0.71
N/A
0.6
21.13
2.04
0.89
0.0248
Operating Margin
N/A
-5.96
N/A
-5.96
-1.03
-1.75
-15.52
-2.78
N/A
N/A
Current Asset
22.72 M
N/A
N/A
N/A
N/A
9 M
28.93 K
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
N/A
N/A
(113 M)
(136.97 M)
N/A
N/A
N/A
Beta
-0.56
-13.71
1.27
-13.71
1.04
0.4
0.2
2.07
0.19
-4.44
Number Of Employees
7
10
98
10
11
25
7
4
16
2
Shares Outstanding
200.02 M
21.96 M
59.58 M
4.39 B
62.4 M
194.01 M
3.89 M
119.74 M
391.11 M
31.19 M
Cash Flow From Operations
(6.51 M)
(35.72 M)
(461.59 M)
(35.72 M)
(2.98 M)
(4.4 M)
(4.31 M)
(6.06 M)
(4.43 M)
(262.9 K)
Total Debt
2.88 M
396 K
189.16 M
396 K
2.31 M
2.1 M
254.36 K
2.36 M
9.8 M
N/A
Return On Equity
-12.06
-0.33
-0.62
-0.33
N/A
-0.33
-39.56
-2.48
0.5
-10.59
Z Score
8.7
N/A
1.2
N/A
27.9
-2.6
N/A
N/A
1.2
-3.3
Return On Asset
-1.04
-0.12
-0.25
-0.12
-0.38
-0.19
-10.02
-0.22
-0.13
-0.8
Number Of Shares Shorted
2.27 K
N/A
N/A
N/A
N/A
N/A
35.47 K
N/A
662.75 K
N/A
Book Value Per Share
-0.005
7.6
N/A
0.038
-0.072
0.098
-0.86
0.026
0.062
-0.017
Current Liabilities
2.32 M
N/A
N/A
N/A
N/A
1000 K
4.97 M
N/A
N/A
N/A
Total Asset
3.73 M
251.62 M
1.46 B
251.62 M
621.64 K
24.48 M
1.64 M
25.64 M
23.61 M
404.12 K
Debt To Equity
0.026
0.025
0.21
0.025
N/A
0.096
0.28
7.75
0.4
285.7
Short Ratio
3.83
N/A
N/A
N/A
N/A
N/A
6.65
N/A
8.04
N/A
Target Price
N/A
N/A
N/A
N/A
4.75
N/A
12.0
N/A
4.0
N/A
Shares Owned By Institutions
13.1
N/A
38.71
22.16
N/A
23.14
0.11
N/A
N/A
N/A
Market Capitalization
29.76 M
128.93 M
504.72 M
120.99 M
120.74 M
12.13 M
27.22 M
1.34 M
23.9 M
31.19 M
Price To Earning
-6.52
N/A
N/A
N/A
237.0
-1.12
-1.95
N/A
2.16
N/A
Price To Sales
N/A
19.41
14.67
22.16
38.19
3.97
130.22
0.79
8.4
0.004
Net Income
(6.56 M)
(34.7 M)
(500.29 M)
(34.7 M)
(1.39 M)
(3.64 M)
(13.38 M)
(13.09 M)
(9.39 M)
(765.84 K)
Earnings Per Share
-0.043
-1.5
N/A
-0.01
0.01
-0.017
-2.18
-0.13
0.02
-0.028
Shares Owned By Insiders
18.35
N/A
14.22
3.68
19.18
22.09
63.48
13.55
55.93
45.87
Revenue
N/A
3.32 M
229.35 M
3.32 M
N/A
2.99 M
157.22 K
4 M
N/A
N/A
Working Capital
20.41 M
N/A
N/A
N/A
N/A
8 M
(406.38 K)
N/A
N/A
N/A
Cash And Equivalents
1.88 M
29.87 M
N/A
29.87 M
585.57 K
14.61 M
5.08 M
94.89 K
399.77 K
17.29 K
Cash Per Share
0.01
1.07
N/A
0.01
0.01
0.08
0.54
N/A
N/A
N/A
Gross Profit
N/A
2.57 M
229.35 M
2.57 M
(502.88 K)
1.83 M
66.21 K
(995.65 K)
1.74 M
N/A
Day Typical Price
1.73
3.85
0.7
2.98
0.89
0.1
7.33
1.0E-4
0.0781
1.5
Accumulation Distribution
N/A
N/A
N/A
0.0328
0.0222
N/A
0.13
N/A
0.16
N/A
Market Facilitation Index
N/A
N/A
N/A
0.1
0.02
N/A
1.0
N/A
0.0136
N/A
Daily Balance Of Power
0.0
9.2 T
9.2 T
(1.00)
(0.50)
0.0
(0.28)
0.0
(0.15)
0.0
Period Momentum Indicator
N/A
0.43
0.15
(0.10)
(0.01)
N/A
(0.28)
N/A
(0)
N/A
Rate Of Daily Change
1.0
1.13
1.27
0.97
0.99
1.0
0.96
1.0
0.98
1.0
Day Median Price
1.73
3.85
0.7
3.0
0.89
0.1
7.5
1.0E-4
0.0782
1.5
Price Action Indicator
N/A
0.22
0.075
(0.10)
0.005
N/A
(0.64)
N/A
(0)
N/A
Relative Strength Index
100.0
48.84
33.76
45.67
57.03
55.1
48.11
N/A
50.93
N/A
Coefficient Of Variation
812.4
1302.67
640.74
2247.03
(9,748)
1733.83
(2,601)
N/A
1710.56
(812.40)
Mean Deviation
5.62
6.25
60.83
6.02
2.08
8.13
6.59
N/A
4.66
0.4552
Jensen Alpha
3.2
1.34
30.23
0.5753
0.0268
1.26
(0.40)
N/A
0.3118
(0.20)
Total Risk Alpha
0.3576
(0.56)
8.71
(0.81)
(0.40)
(0.82)
(1.51)
N/A
(0.39)
(0.44)
Sortino Ratio
N/A
0.0741
0.7931
0.0341
N/A
0.0402
N/A
N/A
0.0335
N/A
Downside Variance
N/A
307.28
1226.47
202.66
N/A
455.73
N/A
N/A
120.25
N/A
Standard Deviation
23.18
18.03
178.51
12.83
3.29
16.37
10.31
N/A
7.75
1.88
Kurtosis
66.0
37.86
31.14
12.84
8.62
10.84
1.63
N/A
1.99
66.0
Potential Upside
N/A
9.59
28.95
10.91
3.03
29.87
16.92
N/A
14.29
N/A
Treynor Ratio
(0.61)
3.13
(0.88)
(2.95)
0.0467
(0.22)
9.52
N/A
0.2538
0.4901
Maximum Drawdown
188.33
132.3
1027.16
78.78
19.05
128.67
55.7
N/A
38.33
15.25
Variance
537.42
325.18
31865.69
164.6
10.84
267.84
106.26
N/A
60.08
3.53
Market Risk Adjusted Performance
(0.60)
3.14
(0.87)
(2.94)
0.0567
(0.21)
9.53
N/A
0.2638
0.5001
Risk Adjusted Performance
0.0961
0.0635
0.1195
0.0407
7.0E-4
0.05
(0.02)
N/A
0.0501
(0.08)
Skewness
8.12
4.53
5.54
0.3713
1.0
1.79
(0.02)
N/A
0.9356
(8.12)
Semi Deviation
N/A
10.05
19.48
10.91
N/A
9.92
N/A
N/A
5.0
N/A
Information Ratio
0.1194
0.072
0.1556
0.0379
(0.04)
0.0525
(0.05)
N/A
0.0475
(0.17)
Value At Risk
N/A
(7.41)
(27.16)
(9.19)
(5.26)
(16.67)
(20.26)
N/A
(10.00)
N/A
Expected Short fall
N/A
(10.68)
(212.93)
(6.95)
N/A
(27.79)
N/A
N/A
(14.01)
N/A
Downside Deviation
N/A
17.53
35.02
14.24
N/A
21.35
N/A
N/A
10.97
N/A
Semi Variance
N/A
101.03
379.32
118.95
N/A
98.47
N/A
N/A
24.98
N/A

Helix BioPharma Competition Performance Charts

Five steps to successful analysis of Helix BioPharma Competition

Helix BioPharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Helix BioPharma Corp in relation to its competition. Helix BioPharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Helix BioPharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Helix BioPharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Helix BioPharma Corp, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Helix BioPharma position

In addition to having Helix BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Mid Cap ETFs Thematic Idea Now

Mid Cap ETFs
Mid Cap ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 76 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Helix Pink Sheet

Helix BioPharma financial ratios help investors to determine whether Helix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY